Ovarian Stem Cell Biology and the Emergence of Ovarian Cancer Stem Cells

Kusumbe, Anjali P.; Bapat, Sharmila A.

doi:10.1002/9780470391594.ch6

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer appears to represent a group of distinct diseases rather than being a single entity. Three broad histological types based on their cell of origin, with distinct frequencies of occurrence, are identified (Boring et al 1993, Kusumbe & Bapat 2008, which are as follows:…”

Section: Ovarian Cancer and Stem Cellsmentioning

confidence: 99%

Human ovarian cancer stem cells

Bapat¹

2010

Reproduction

View full text Add to dashboard Cite

The isolation and identification of stem-like cells in solid tumors or cancer stem cells (CSCs) have been exciting developments of the last decade, although these rare populations had been earlier identified in leukemia. CSC biology necessitates a detailed delineation of normal stem cell functioning and maintenance of homeostasis within the organ. Ovarian CSC biology has unfortunately not benefited from a pre-established knowledge of stem cell lineage demarcation and functioning in the normal organ. In the absence of such information, some of the classical parameters such as long-term culture-initiating assays to isolate stem cell clones from tumors, screening and evaluation of other epithelial stem cell surface markers, dye efflux, and label retention have been applied toward the putative isolation of CSCs from ovarian tumors. The present review presents an outline of the various approaches developed so far and the various perspectives revealed that are now required to be dealt with toward better disease management.

show abstract

Section: Ovarian Cancer and Stem Cellsmentioning

confidence: 99%

Human ovarian cancer stem cells

Bapat¹

2010

Reproduction

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is the seventh leading cause of cancer-related mortality with a severe impact on socioeconomic and community health, globally 1–4. Compared to other types of gynecologic malignancies, ovarian cancer has the highest mortality rate in developed countries worldwide 5–7.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, it is the seventh leading cause of cancer-related mortality with a severe impact on socioeconomic and community health, globally. 1 – 4 Compared to other types of gynecologic malignancies, ovarian cancer has the highest mortality rate in developed countries worldwide. 5 – 7 The American Cancer Society estimated that 22,240 women were going to be diagnosed with ovarian cancer in the US in 2013, while the number of ovarian cancer-related deaths was estimated to be 14,230.…”

Section: Introductionmentioning

confidence: 99%

Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008

Alghamdi¹,

Hussain²,

Alghamdi³

et al. 2014

IJWH

View full text Add to dashboard Cite

PurposeThis study provides descriptive epidemiological data, such as the percentage of cases diagnosed, crude incidence rate (CIR), and age-standardized incidence rate (ASIR) of ovarian cancer in Saudi Arabia from 2001–2008.Patients and methodsA retrospective descriptive epidemiological analysis of all ovarian cancer cases recorded in the Saudi Cancer Registry (SCR) from January 2001–December 2008 was performed. The data were analyzed using descriptive statistics, analysis of variance tests, Poisson regression, and simple linear modeling.ResultsA total of 991 ovarian cancer cases were recorded in the SCR from January 2001–December 2008. The region of Riyadh had the highest overall ASIR at 3.3 cases per 100,000 women, followed by the Jouf and Asir regions at 3.13 and 2.96 cases per 100,000 women. However, Hail and Jazan had the lowest rates at 1.4 and 0.6 cases per 100,000 women, respectively. Compared to Jazan, the incidence rate ratio for the number of ovarian cancer cases was significantly higher (P<0.001) in the Makkah region at 6.4 (95% confidence interval [CI]: 4.13–9.83), followed by Riyadh at 6.3 (95% CI: 4.10–9.82), and the eastern region of Saudi Arabia at 4.52 (95% CI: 2.93–6.98). The predicted annual CIR and ASIR for ovarian cancer in Saudi Arabia could be defined by the equations 0.9 + (0.07× years) and 1.71 + (0.09× years), respectively.ConclusionWe observed a slight increase in the CIRs and ASIRs for ovarian cancer in Saudi Arabia from 2001–2008. Riyadh, Jouf, and Asir had the highest overall ASIR, while Jazan and Hail had the lowest rates. Makkah, Riyadh, and the eastern region of Saudi Arabia had the highest incidence rate ratio for the number of ovarian cancer cases. Further analytical studies are required to determine the potential risk factors of ovarian cancer among Saudi women.

show abstract

“…Because of this long and characteristic diffusion, radical surgery plays an important role in the diagnosis, staging, primary therapy, and treatment of recurrent disease 3. Standard therapy includes cytoreductive surgery preceded or followed by platinum/taxane combination chemotherapy (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Current status of bevacizumab in advanced ovarian cancer

Tomao

Papa²,

Rossi³

et al. 2013

OTT

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.

show abstract

Ovarian Stem Cell Biology and the Emergence of Ovarian Cancer Stem Cells

Cited by 6 publications

References 31 publications

Human ovarian cancer stem cells

Human ovarian cancer stem cells

Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008

Current status of bevacizumab in advanced ovarian cancer

Contact Info

Product

Resources

About

Ovarian Stem Cell Biology and the Emergence of Ovarian Cancer Stem Cells

Cited by 6 publications

References 31 publications

Human ovarian cancer stem cells

Human ovarian cancer stem cells

Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001&ndash;2008

Current status of bevacizumab in advanced ovarian cancer

Contact Info

Product

Resources

About

Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008